R Maini

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group
    R Maini
    The Kennedy Institute of Rheumatology and The Imperial College School of Medicine at Charing Cross Hospital, London, UK
    Lancet 354:1932-9. 1999
  2. ncbi request reprint Anti-cytokine therapy for rheumatoid arthritis
    R N Maini
    Kennedy Institute of Rheumatology, London, UK
    Annu Rev Med 51:207-29. 2000
  3. pmc How does infliximab work in rheumatoid arthritis?
    Ravinder N Maini
    The Kennedy Institute of Rheumatology Division, Imperial College of Science Technology and Medicine, London, UK
    Arthritis Res 4:S22-8. 2002
  4. pmc Current and new antitumor necrosis factor agents in perspective
    Ravinder N Maini
    Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK
    Arthritis Res Ther 6:S1-2. 2004
  5. ncbi request reprint Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
    E William St Clair
    Duke University Medical Center, Durham, North Carolina, USA
    Arthritis Rheum 50:3432-43. 2004
  6. ncbi request reprint Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:702-10. 2006
  7. ncbi request reprint Infliximab treatment maintains employability in patients with early rheumatoid arthritis
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:716-22. 2006
  8. pmc Interleukin-6: a new therapeutic target
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:S5. 2006
  9. ncbi request reprint The pitfalls in the development of biologic therapy
    Ravinder N Maini
    Nat Clin Pract Rheumatol 3:1. 2007
  10. ncbi request reprint The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis
    Marc Feldmann
    Kennedy Institute of Rheumatology Division, Imperial College, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK
    Best Pract Res Clin Rheumatol 18:59-80. 2004

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group
    R Maini
    The Kennedy Institute of Rheumatology and The Imperial College School of Medicine at Charing Cross Hospital, London, UK
    Lancet 354:1932-9. 1999
    ..We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate...
  2. ncbi request reprint Anti-cytokine therapy for rheumatoid arthritis
    R N Maini
    Kennedy Institute of Rheumatology, London, UK
    Annu Rev Med 51:207-29. 2000
    ..One anti-TNF reagent has already been approved in the United States for the treatment of RA, and other cytokine antagonists or agonists are under development...
  3. pmc How does infliximab work in rheumatoid arthritis?
    Ravinder N Maini
    The Kennedy Institute of Rheumatology Division, Imperial College of Science Technology and Medicine, London, UK
    Arthritis Res 4:S22-8. 2002
    ....
  4. pmc Current and new antitumor necrosis factor agents in perspective
    Ravinder N Maini
    Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK
    Arthritis Res Ther 6:S1-2. 2004
  5. ncbi request reprint Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
    E William St Clair
    Duke University Medical Center, Durham, North Carolina, USA
    Arthritis Rheum 50:3432-43. 2004
    ....
  6. ncbi request reprint Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:702-10. 2006
    ..To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX...
  7. ncbi request reprint Infliximab treatment maintains employability in patients with early rheumatoid arthritis
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:716-22. 2006
    ..To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA)...
  8. pmc Interleukin-6: a new therapeutic target
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:S5. 2006
    ..Here, we review recent phase II trials of tocilizumab, a humanized anti-IL-6 receptor antibody that achieves a significant therapeutic response rate...
  9. ncbi request reprint The pitfalls in the development of biologic therapy
    Ravinder N Maini
    Nat Clin Pract Rheumatol 3:1. 2007
  10. ncbi request reprint The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis
    Marc Feldmann
    Kennedy Institute of Rheumatology Division, Imperial College, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK
    Best Pract Res Clin Rheumatol 18:59-80. 2004
    ..The development of anti-TNF therapy is a key step forward in rheumatology as it is the first new therapy for based on investigating the molecular mechanisms of this disease. This chapter reviews how this discovery was made...
  11. ncbi request reprint Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
    Marc Feldmann
    Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, London W6 8LH, UK
    Novartis Found Symp 256:53-69; discussion 69-73, 106-11, 266-9. 2004
    ..The era of anti-cytokine therapeutics is just dawning...
  12. ncbi request reprint Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases
    Marc Feldmann
    Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College, 1 Aspenlea Road, London W6 8LH, UK
    Nat Med 9:1245-50. 2003
  13. ncbi request reprint Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers
    Peter E Lipsky
    Arthritis Rheum 46:2817-8; author reply 2718-21. 2002
  14. ncbi request reprint Cytokines and anti-cytokine biologicals in autoimmunity: present and future
    Evangelos T Andreakos
    Faculty of Medicine, Kennedy Institute of Rheumatology Division, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK
    Cytokine Growth Factor Rev 13:299-313. 2002
    ..The future developments of anti-TNFalpha and anti-cytokine therapy in general will be interesting...
  15. ncbi request reprint Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies
    Marc Feldmann
    Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College, London, UK
    Joint Bone Spine 69:12-8. 2002
    ..There is now extensive clinical use of anti-TNFalpha biologicals for severe rheumatoid arthritis in the US and Europe...
  16. doi request reprint Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
    Michael J Elliot
    Clinical Immunology Division, Kennedy Institute of Rheumatology, London W6 7DW, United Kingdom
    Arthritis Rheum 58:S92-S101. 2008
    ..To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA)...
  17. ncbi request reprint Gene studies, anti-TNF therapy take Lasker honors
    Mike Mitka
    JAMA 290:1979-80. 2003
  18. ncbi request reprint A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content
    Eng M Tan
    Autoantibody Standardization Committee in Rheumatic and Related Disorders of the International Union of Immunological Societies, The World Health Organization, The Arthritis Foundation, and Centers for Disease Control and Prevention
    J Rheumatol 29:68-74. 2002
    ..To analyze the performance of different commercial enzyme immunoassay (EIA) kits for measuring antibody levels of antinuclear antibodies (ANA) specific for double stranded (ds) DNA, SSB/La, Sm, and Scl-70...